NCT Number: NCT02910284
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
This study is a follow-up study from Study GEN-003-002 to evaluate long-term efficacy and immunogenicity of GEN-003 in subjects with genital HSV-2 infection.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–50 year
Sex eligibility
All sexes
Study type
Observational
Primary location
University of Alabama - Birmingham, Birmingham, Alabama, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Completion of Study GEN-003-002
- Receipt of at least 1 dose of GEN-003 (any dose combination) in Study GEN-003-002.
- Collection of at least 45 of 56 anogenital swabs during the Month 11 to 12 swab collection period in Study GEN-003-002.
- Willing and able to provide written informed consent.
- Willing to perform and comply with all study procedures, including attending clinic visits as scheduled.
- For each swab collection period, willing to not use HSV-2 antiviral therapy from 14 days before the swab collection period through the end of the period.
Exclusion criteria
- Any important protocol deviation in Study GEN-003-002.
- Use of HSV-2 antiviral therapy within 14 days before the beginning of Swab Collection Period 1.
- Use of topical steroids or antiviral medication in the anogenital region within 14 days before the beginning of Swab Collection Period 1.
- Use of tenofovir, lysine, or other medication or supplement known or purported to affect HSV outbreak frequency or intensity within 14 days before the beginning of Swab Collection Period 1.
- Immunocompromised individuals, including those receiving immunosuppressive doses of corticosteroids (more than 20 mg of prednisone given daily or on alternative days for 2 weeks or more within 6 months before the Visit 1, any dose of corticosteroids within 30 days before Visit 1, or high-dose inhaled corticosteroids [>960 µg/day of beclomethasone diproprionate or equivalent]) or other immunosuppressive agents.
- Presence or history of autoimmune disease, regardless of current treatment.
- Receipt of a vaccine containing HSV-2 antigens other than GEN-003.
- Pregnant women.
- History of drug or alcohol abuse that, in the opinion of the Investigator, would interfere with the patient's ability to comply with the requirements of the study.
- Onset of an AESI since Month 12 in study GEN-003-002.
- Other active, uncontrolled comorbidities that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with the study requirements.
Treatment and study plan
Primary outcomes
-
Long-term effect of GEN-003 on anogenital Herpes simplex virus type 2 (HSV-2) shedding (percent of anogenital swabs positive for HSV-2 DNA by PCR)
Time frame: Up to 48 months post-dose
-
Long-term effect of GEN-003 on anogenital Herpes simplex virus type 2 (HSV-2) shedding (magnitude of HSV-2 viral shedding by PCR)
Time frame: Up to 48 months post-dose
Secondary outcomes
-
Long-term effect of GEN-003 on HSV-lesion rate (percent of days with genital lesions present) during the swab collection periods
Time frame: Up to 48 months post-dose
-
Long-term immune responses to GEN-003 (Serum IgG levels assessed by ELISA)
Time frame: Up to 48 months post-dose
-
Long-term immune responses to GEN-003 (Serum HSV-2 neutralizing antibody levels assessed by a colorimetric neutralization assay)
Time frame: Up to 48 months post-dose
-
Long-term immune responses to GEN-003 (Spot-forming units (SFUs), fold rise, responder rate assessed by GrB ELISPOT)
Time frame: Up to 48 months post-dose
Sponsors and collaborators
Lead sponsor
Genocea Biosciences, Inc.
Industry
Registry information
Official study title
A Long-term Follow-up Study of Efficacy and Immunogenicity of GEN-003 in Subjects With Genital Herpes Simplex Virus Type 2 (HSV-2) Infection
Important dates
- Study start
- 2016
- Primary completion
- 2017
- Study completion
- 2017
- First posted
- Sep 22, 2016
- Registry last updated
- Oct 20, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Evaluating New Formulation of Therapeutic HSV-2 Vaccine
NCT02515175
Communicable Diseases, DNA Virus Infections
Birmingham, Alabama, United States
View Trial DetailsSafety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults
NCT02030301
DNA Virus Infections, Genital Herpes Simplex Type 2
Birmingham, Alabama, United States
View Trial DetailsSafety and Immunogenicity Study of Therapeutic HSV-2 Vaccine
NCT01667341
DNA Virus Infections, Genital Herpes Simplex Type 2
Birmingham, Alabama, United States
View Trial DetailsDose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine
NCT02114060
DNA Virus Infections, Genital Herpes Simplex Type 2
Birmingham, Alabama, United States
View Trial Details